50 Participants Needed

Registry for Brain Tumor

Recruiting at 7 trial locations
AP
Ingo Mellinghoff, MD profile photo
Overseen ByIngo Mellinghoff, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Memorial Sloan Kettering Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to gather detailed information about individuals with a specific type of brain tumor linked to neurofibromatosis type 1 (NF1). It will collect medical records and conduct surveys to understand how different treatments affect these tumors and the lives of those affected. By creating a registry (a health information database), researchers hope to improve diagnosis and treatment methods for future patients. Individuals diagnosed with NF1 and a glioma (a type of brain tumor) who are willing to share their health records might be a good fit for this trial. As an unphased study, this trial offers a unique opportunity to contribute to a deeper understanding of NF1-related gliomas, potentially benefiting future patients.

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications. It seems to focus on collecting health information rather than changing treatments.

Why are researchers excited about this trial?

Researchers are excited about the Glioma Developmental and HyperActive Ras Tumor (DHART) Board registry study because it aims to gather comprehensive data on glioma, a type of brain tumor. Unlike traditional treatments like surgery, radiation, and chemotherapy, this registry isn't a treatment itself but a powerful tool for understanding how gliomas develop and respond to various treatments. By collecting detailed patient information, it helps identify patterns and potential new targets for future therapies, paving the way for more personalized and effective treatment strategies. This approach could significantly enhance our understanding of gliomas and improve treatment outcomes over time.

Who Is on the Research Team?

AP

Anna Piotrowski

Principal Investigator

Memorial Sloan Kettering Cancer Center

Are You a Good Fit for This Trial?

Inclusion Criteria

Clinical diagnosis that meets NIH criteria for NF1 disease by either 1) documented clinical record establishing NF1 or 2) self-reported with supported documentation upon medical record collection.
Willing to have historical and future NF1 related health records sent to registry for review.
Radiologic or pathologically confirmed glioma.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Data Collection

Collection of medical records, scan results, and completion of surveys to create a registry

5 years

Follow-up

Participants are monitored for changes in diagnosis, treatment, and quality of life over time

5 years

What Are the Treatments Tested in This Trial?

Interventions

  • Registry Study

Find a Clinic Near You

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials
1,998
Recruited
602,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security